'Always average down with biotech start-up stock when there hasn't been any fundamental change since the market doesn't know how to correctly value them until the end game.'
Very high-risk strategy. Sure, early-stage biotechs can be underpriced, especially with no revenue and lots of uncertainty, but they also frequently go to zero. Averaging down might work, but it's far from safe.
IMU Price at posting:
1.4¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)